Telix Pharmaceuticals Ltd. ( (AU:TLX) ) just unveiled an announcement.
Telix Pharmaceuticals Ltd. has announced its full year results for FY2024, highlighting the approval and market presence of its lead imaging product, Illuccix®, across multiple jurisdictions, including the U.S., Australia, and Canada. The company’s osteomyelitis imaging agent, Scintimun®, is also approved in 32 European countries and Mexico. This expansion in product approvals signifies a strengthening of Telix’s market position in the medical imaging industry, potentially leading to increased revenue and a stronger competitive stance in the biopharmaceutical sector.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd. is a biopharmaceutical company that operates in the medical imaging and oncology sectors. The company specializes in developing diagnostic and therapeutic products, including imaging agents such as gallium-68 (Ga) gozetotide and technetium-99m (Tc) besilesomab, marketed under the brand names Illuccix® and Scintimun®, respectively. Telix’s products are approved in several major markets, including the U.S., Australia, Canada, and parts of Europe.
YTD Price Performance: 22.55%
Average Trading Volume: 4,376
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $5.81B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.